Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Apr 30;21(1):479.
doi: 10.1186/s12885-021-08234-4.

Prognostic value of ubiquitin E2 UBE2W and its correlation with tumor-infiltrating immune cells in breast cancer

Yan Yuan #  1   2 , Wei-Wei Xiao #  1   2 , Wei-Hao Xie #  1   2 , Rong-Zhen Li  1   2 , Yuan-Hong Gao  3   4
Affiliations

Prognostic value of ubiquitin E2 UBE2W and its correlation with tumor-infiltrating immune cells in breast cancer

Yan Yuan et al. BMC Cancer. .

Abstract

Background: Ubiquitin-conjugating enzyme E2W (UBE2W) is a protein-coding gene that has an important role in ubiquitination and may be vital in the repair of DNA damage. However, studies on the prognostic value of UBE2W and its correlation with tumor-infiltrating immune cells in multiple cancers have not been addressed.

Methods: We investigated UBE2W expression in the Oncomine database, the Tumor Immune Estimation Resource (TIMER), TNMplot database. Then, the clinical prognostic value of UBE2W was analyzed via online public databases. Meanwhile, we explored the correlation between UBE2W and DNA repair associate genes expression and DNA methyltransferase expression by TIMER and Gene Expression Profiling Interactive Analysis (GEPIA). By using the same method, the correlation between UBE2W and tumor-infiltrating immune cells was explored. Genomic Profiles of UBE2W in breast cancer (BRCA) were accessed in cBioPortal (v3.5.0). Functional proteins associated network was analyzed by STRING database (v11.0).

Results: UBE2W was abnormally expressed and significantly correlated with mismatch repair (MMR) gene mutation levels, DNA methyltransferase, and BRCA1/2 expression in breast cancer. High expression of UBE2W may promote the tumor immunosuppression and metastasis, induce endocrine therapy resistance and deteriorate outcomes of patients with breast cancer. These findings suggest that UBE2W could be a potential biomarker of prognosis and tumor-infiltrating immune cells. Besides, RBX1 may be a new E3 that was regulated by UBE2W.

Conclusions: Ubiquitin E2 UBE2W is a potential prognostic biomarker and is correlated with immune infiltration in BRCA.

Keywords: Breast cancer; Endocrine therapy resistance; Prognosis; Tumor immune environment; UBE2W.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest.

Figures

Fig. 1
Fig. 1
Expression of UBE2W in various human tumors. a Increased expression of UBE2W in different tumors compared to normal tissues in the Oncomine database. b UBE2W expression of different tumor types from the TCGA database was investigated by TIMER (*P < 0.05, **P < 0.01, ***P < 0.001). c UBE2W was abnormally expressed in pan cancers by TNMplot. Significant differences by Mann-Whitney U test are marked with red color. Abbreviations: ACC: adrenocortical carcinoma; BLCA: bladder urothelial carcinoma; BRCA: breast invasive carcinoma; CESC: cervical squamous cell carcinoma; CHOL: cholangiocarcinoma; COAD: colon adenocarcinoma; DLBC: lymphoid neoplasm diffuse large B cell lymphoma; ESCA: esophageal carcinoma; GBM: glioblastoma multiforme; LGG: brain lower grade glioma; HNSC: head and neck squamous cell carcinoma; KICH: kidney chromophobe; KIRC: kidney renal clear cell carcinoma; KIRP: kidney renal papillary cell carcinoma; LAML: acute myeloid leukemia; LIHC: liver hepatocellular carcinoma; LUAD: lung adenocarcinoma; LUSC: lung squamous cell carcinoma; MESO: mesothelioma; OV: ovarian serous cystadenocarcinoma; PAAD: pancreatic adenocarcinoma; PCPG: pheochromocytoma and paraganglioma; PRAD: prostate adenocarcinoma; READ: rectum adenocarcinoma; SARC: sarcoma; SKCM: skin cutaneous melanoma; STAD: stomach adenocarcinoma; TGCT: testicular germ cell tumors; THCA: thyroid carcinoma; THYM: thymoma; UCEC: uterine corpus endometrial carcinoma; UCS: uterine carcinosarcoma; and UVM: uveal melanoma; AML: ; Lung_AC: lung adenocarcinoma; Lung_SC: lung squamous cell carcinoma; Renal_CC: renal clear cell carcinoma; Renal_CH: renal chromophobe cell carcinoma; Renal_PA: renal papillary cell carcinoma; Uterus_CS: uterine carcinosarcoma; Uterus_EC: uterine corpus endometrial carcinoma
Fig. 2
Fig. 2
Survival analysis and predictive value analysis of UBE2W in public databases. a-c Overall survival (OS), Relapse free survival (RFS), and Distant metastasis-free survival curves of BRCA by different expression levels of UBE2W in the K-M plotter database. d-e OS and RFS curves of BRCA by different expression levels of UBE2W in the PrognoScan database. f Gene chip data of UBE2W expression in normal, tumor, metastatic tissues. g RNA-seq data of UBE2W expression in normal, tumor, metastatic tissues. h UBE2W expression between responders and non-responders in endocrine therapy of BRCA. i The ROC plot of UBE2W expression in predicting the effect of endocrine therapy in BRCA. Abbreviations: OS: overall survival; RFS: relapse-free survival; DMFS: distant metastasis free survival
Fig. 3
Fig. 3
Correlation of UBE2W expression with DNA repair and DNA methyltransferase genes in BRCA
Fig. 4
Fig. 4
Correlation of UBE2W expression with immune infiltration level in BRCA
Fig. 5
Fig. 5
Genomic alterations of UBE2W of BRCA in cBioPortal. a Oncoprint of UBE2W alteration in BRCA. b Mutation details for UBE2W. c, d Survival analysis. Abbreviations: OS: overall survival
See this image and copyright information in PMC

References

    1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi: 10.3322/caac.21492. - DOI - PubMed
    1. Hartman M, Loy EY, Ku CS, Chia KS. Molecular epidemiology and its current clinical use in cancer. Lancet Oncol. 2010;11(4):383–390. doi: 10.1016/S1470-2045(10)70005-X. - DOI - PubMed
    1. Hoeller D, Hecker CM, Dikic I. Ubiquitin and ubiquitin-like proteins in cancer pathogenesis. Nat Rev Cancer. 2006;6(10):776–788. doi: 10.1038/nrc1994. - DOI - PubMed
    1. Kleiger G, Mayor T. Perilous journey: a tour of the ubiquitin–proteasome system. Trends Cell Biol. 2014;24(6):352–359. doi: 10.1016/j.tcb.2013.12.003. - DOI - PMC - PubMed
    1. Ebstein F, Keller M, Paschen A, Walden P, Seeger M, Burger E, Kruger E, Schadendorf D, Kloetzel PM, Seifert U. Exposure to Melan-a/MART-126-35 tumor epitope specific CD8(+)T cells reveals immune escape by affecting the ubiquitin-proteasome system (UPS) Sci Rep. 2016;6(1):25208. doi: 10.1038/srep25208. - DOI - PMC - PubMed

MeSH terms

LinkOut - more resources